Decentralized Pharmacy Procurement Is Costing Your Health System More Than You Know

Your pharmacy teams are working hard. Your contracts are in place. Your wholesaler relationships are solid. And somehow, drug spend still keeps climbing.

It's not a purchasing effort problem. It's a purchasing structure problem.

For most health systems, pharmacy procurement didn't end up fragmented on purpose. It happened the way most operational complexity does: gradually, then all at once. Each acquisition brought its own systems, its own vendor relationships and its own habits. Nobody chose decentralization. They inherited it. And now they're paying for it in ways that rarely show up clearly on any single report.

U.S. non-federal hospitals spent $39 billion on drugs in 2024, a 4.9% year-over-year increase according to ASHP. The same report projected hospital drug spending would rise another 2% to 4% in 2025, with clinic drug spending projected to rise 11% to 13% as more care continues shifting into outpatient settings. Against that backdrop, the structural inefficiencies baked into decentralized procurement are not just inconvenient. They are a liability that compounds every single day.

How Health Systems Got Here (And Why It's Hard to See the Problem)

Decentralization is a byproduct of growth, not a failure of planning. Over the past decade, health systems have expanded through mergers, acquisitions and new sites of care. Kaufman Hall reported 46 announced hospital and health system transactions in 2025, followed by 22 more in Q1 2026. But M&A is only part of the story. As care shifts further into outpatient and patient-centered settings, health systems are also adding more classes of trade — retail, oncology and infusion, specialty pharmacy and other ambulatory models — each with different drug mixes, NDC volume, purchasing workflows, wholesalers, manufacturers and vendor platforms.

The result is an enterprise that may look coordinated on paper but functions as a collection of independent purchasing units in practice. Inpatient pharmacy, with its heavier reliance on the “Big 3” wholesalers and GPO contracts, is often the most straightforward procurement scenario. Outpatient growth introduces more purchasing variation, more vendor relationships and more places for savings opportunities to be missed.

The real problem? Fragmented data makes fragmented costs invisible. When purchasing decisions happen at the site level, the financial damage spreads across dozens of line items, in dozens of portals and vendor platforms, across dozens of locations. No single report surfaces the full picture. And so most health system leaders know they're leaving money on the table. Few understand exactly how much, or why.

The 5 Cost Categories Silently Draining Your Drug Spend

Ask a pharmacy director what decentralized procurement costs them and they'll describe a workload problem. What they're less likely to quantify is the cumulative financial damage happening across five distinct categories, simultaneously.

Price Leakage

Price leakage does not always come from missing a rebate tier. In many health systems, the larger opportunity comes from the gap between required contract compliance and actual purchasing behavior. If a contract requires 90% compliance but actual purchasing runs above 95%, teams may be protecting the organization from a major rebate mistake, while also giving up opportunities to shift appropriate volume to lower-cost channels. Without enterprise-level visibility, leaders cannot see where compliance is necessary, where it is excessive and where savings are being left behind.

According to SureCost's own procurement data, two-thirds of procurement savings opportunities exist outside the top 200 drugs, where purchasing decisions are most likely to be made without strategic oversight. If your teams aren't seeing those opportunities in real time, they're not capturing them.

Processing Cost

Without systematic invoice scanning and verification, receiving errors go undetected. Uncorrected credits accumulate across the system. Each error is small. Across dozens of sites and thousands of transactions, they add up fast.

Inventory Waste

When each site orders to protect itself against shortages, excess inventory builds system-wide. Drugs expire. Reverse distribution credits are partial at best. The sites feel safe. The enterprise absorbs the loss.

Disruption Cost

There are currently more than 216 active drug shortages, with over 75% starting in 2022 or later and more than half persisting for two years or longer. Meanwhile, a federal analysis found that over 1,900 drug products saw list price increases that outpaced inflation. Shortage drugs carry a significant cost premium over contract price, and when visibility is limited to the site level, health systems can't see what's already on shelves across their enterprise. In response, they continuously place emergency orders on top of inventory they already have, they have to rely on inefficient manual processes to bring key stakeholders together to cobble together the information.

Unrecovered Waste

Expired stock and unreconciled credits represent financial leakage that is difficult to fully recover once it occurs. The money has already left the building, and decentralized purchasing, receiving and inventory processes make it harder to identify, reconcile and recapture every opportunity consistently across the system.

These five categories don't just add up. They compound each other. And they're growing with every new site added to the enterprise.

The Operational Multiplier Behind the Push for Centralization

Beyond the direct financial cost, decentralization imposes an operational tax on every team managing it.

Purchasing and receiving tasks are replicated at every site with no shared process or standardization. In a market where pharmacy technician vacancies exceed 20%, every hour spent on redundant administrative work is an hour that can't be recovered.

When a shortage hits, most health systems can't tell you what's on shelves across their enterprise. Site-level buffering creates excess inventory across the system, while individual locations may continue placing emergency orders because they cannot see what is already available elsewhere.

Purchasing data sits in separate systems, fragmented by site, by class of trade and by vendor portal. You can't run an intelligent enterprise strategy on data you can't see, let alone act on it in real time.

Add the integration overhead of cabinets, pharmacy management systems, EHR and wholesaler portals, and you have a system with more failure points, more manual workarounds and less capacity for strategic work.

Why the Conventional Fixes Fall Short

The instinct is to centralize. The goal is right. The tools most health systems reach for, however, don't get them there.

Retrospective analytics tools tell you where money was lost last quarter. GPO reporting flags compliance gaps after the fact. Neither changes what happens at the point of purchase. In a market where drug prices shift daily, last month's data isn't a decision-making tool. It's a post-mortem.

Central distribution centers and central-fill models introduce structural efficiency but don't resolve the underlying visibility problem. A CDC can consolidate purchasing leverage on a defined formulary. But if satellite sites can still order direct from wholesalers, and they often do, the enterprise still doesn't know what's actually being purchased, where or why.

A CDC or central-fill model gives you structural efficiency. A unified procurement platform gives you operational intelligence. You need both.

What Real Procurement Centralization Actually Looks Like

The best time to optimize a purchasing decision is before it's made.

That's the premise behind a unified procurement platform: surfacing the right information at the point of purchase, not after the invoice has been processed and the opportunity has passed. Price, availability, contract compliance, formulary alignment and GPO impact should all be visible before a buyer commits.

For health systems, that means:

• One vendor catalog. Every supplier — primary wholesaler, GPO contracts, secondaries, direct manufacturer — accessible in a single interface, so buyers stop missing savings from catalogs they didn't check.
• Real-time compliance monitoring. GPO contracts and wholesaler agreements audited at the point of purchase and again at invoice receipt, with discrepancies flagged automatically for recovery.
• System-wide inventory visibility. The ability to see what's on shelves across every site, optimize transfers before placing new orders and reduce the site-level buffering that drives expired stock.
• Standardized receiving. Mobile-enabled, consistent receiving that works the same way regardless of vendor, with DSCSA validation built in.
• Formulary management with accountability. Exceptions flagged, tracked and accounted for so leadership always knows who's buying what and why.
• Integrated financial data. Three-way invoice matching and credit tracking that feeds upstream automatically, so financial systems reflect actual cost of goods.

This isn't a reporting layer. It's the platform your teams work inside every day, at every site, for every purchase.

This Problem Isn't Just for Large Systems

It's tempting to assume that procurement centralization is a large health system problem. It isn't. A three-pharmacy rural system with a staffing-constrained team and a CFO who needs better answers on drug spend can face the same structural challenge at a smaller scale.

The cost categories are the same. The vendor complexity is the same. And the savings opportunity, as a percentage of cost of goods, is the same.

If you're managing procurement across sites without a unified platform, you're paying a fragmentation tax. And it's growing every year.

Looking Ahead: The Health Systems That Win on Margin

The pharmacy financial environment isn't getting easier. Drug spend is climbing. Shortages are compounding. Compliance demands across DSCSA, 340B and vendor agreements are multiplying. And staffing gaps aren't closing anytime soon.

The health systems that protect their pharmacy margins over the next three to five years won't necessarily be the largest. They'll be the ones that figured out how to see every purchase, enforce every strategy and act at the point of decision, not after it.

Decentralized procurement has never been the optimal model. For a long time, it was a manageable one. Today, it's becoming an active liability.

The good news is that the fix doesn't require a multi-year transformation. It requires a platform that brings every site, every vendor and every purchasing decision into one place, before the money walks out the door.

Want a clearer view of where decentralized procurement creates margin leakage?

Download the full SureCost white paper for a deeper breakdown of the five cost categories, the operational multiplier effect and what unified procurement intelligence looks like in practice.